Clinical Trials Using Thalidomide
Clinical trials are research studies that involve people. The clinical trials on this list are studying Thalidomide. All trials on the list are supported by NCI.
NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.
A Phase 2 / 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Phase 3 of this study is evaluating 200 mg BID of pacritinib compared to physician's choice (P / C) therapy in patients with MF and severe thrombocytopenia (platelet count <50,000 / μL). Approximately 180 patients in total will be enrolled, randomized 2:1 to either pacritinib (approximately 120 patients) or to P / C therapy (approximately 60 patients) Phase 2 was an open-label, randomized, dose-ranging study designed to identify the most appropriate dosage of pacritinib for future studies based on risk / benefit profile. Patients were randomized 1:1:1 to three dosage arms: 100mg QD, 100mg BID or 200mg BID. A total of 164 patients were randomized in the phase 2 portion of Study PAC203, and 161 (98.2%) patients received any treatment with pacritinib. Condition or disease: Primary Myelofibrosis / Post-Polycythemia Vera Myelofibrosis / Post-essential Thrombocythemia Myelofibrosis Intervention / treatment: Drug-Pacritinib
Location: 13 locations
Ruxolitinib and Thalidomide in Treating Patients with Newly Diagnosed, Relapsed, or Refractory Myelofibrosis
This phase II trial studies how well ruxolitinib and thalidomide work in treating patients with myelofibrosis that is newly diagnosed, has come back (relapsed), or does not respond to treatment (refractory). Ruxolitinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Thalidomide may shrink cancer and reduce the number of blood transfusion needed. Giving ruxolitinib and thalidomide may work better in treating patients with myelofibrosis.
Location: 8 locations
Cyclophosphamide or Thalidomide after Stem Cell Transplant in Treating Younger Patients with Solid Tumors
This early phase I pilot clinical trial studies cyclophosphamide or thalidomide following high dose chemotherapy and stem cell transplant in treating younger patients with solid tumors. Drugs such as cyclophosphamide and thalidomide suppress the growth of new blood vessels to tumors. Blocking blood flow to tumors after receiving high dose chemotherapy and a stem cell transplant may prevent the tumors from coming back or continuing to grow.
Location: 2 locations
Metronomic and Targeted Anti-angiogenesis Therapy for Children With Recurrent / Progressive Medulloblastoma
Patients with relapsed medulloblastoma have a very poor prognosis whether treated with conventional chemotherapy, high-dose chemotherapy with stem cell rescue, irradiation or combinations of these modalities. Antiangiogenetic therapy has emerged as new treatment option in solid malignancies. The frequent, metronomic schedule targets both proliferating tumor cells and endothelial cells, and minimizes toxicity. In this study the investigators will evaluate the use of biweekly intravenous bevacizumab in combination with five oral drugs (thalidomide, celecoxib, fenofibrate, and alternating cycles of daily low-dose oral etoposide and cyclophosphamide), augmented with alternating courses of intrathecal etoposide and cytarabine. The aim of the study is to extend therapy options for children with recurrent or progressive medulloblastoma, for whom no known curative therapy exists, by prolonging survival while maintaining good quality of life. The primary objective of the MEMMAT trial is to evaluate the activity of this multidrug antiangiogenic approach in these heavily pretreated children and young adults. Additionally, progression-free survival (PFS), overall survival (OS), as well as feasibility and toxicity will be examined.
Location: 3 locations